scholarly journals First-in-man feasibility study of a novel ingestible magnetically inflated balloon capsule for treatment of obesity

2020 ◽  
Vol 08 (05) ◽  
pp. E607-E610 ◽  
Author(s):  
Hung Leng Kaan ◽  
Phuoc Thien Phan ◽  
Anthony Meng Huat Tiong ◽  
Muneaki Miyasaka ◽  
Soo Jay Phee ◽  
...  
Keyword(s):  
Feasibility Study ◽  
Animal Studies ◽  
Obese Patients ◽  
Proof Of Concept ◽  
External Magnet ◽  
Inflated Balloon ◽  
Term Efficacy ◽  
Treatment Of Obesity ◽  
Established Treatment

AbstractIntragastric balloons (IGBs) are an established treatment option for obesity. Major barriers to dissemination of IGBs include lack of long-term efficacy outcomes, safety concerns, cost, and tolerability. We developed a novel ingestible magnetically inflated balloon capsule (IMI-BC) in hopes of overcoming these challenges. The IMI-BC is significantly cheaper than IGBs currently available on the market. We performed proof-of-concept animal studies and a first-in-human feasibility study to demonstrate the feasibility of inflating the IMI-BC using an external magnet. Further studies are currently being conducted to evaluate the safety, tolerability, and long-term efficacy of the IMI-BC. When fully developed, we anticipate that this device will benefit obese patients.

Short- and Long-Term Efficacy of Intragastric Air-Filled Balloon (Heliosphere® BAG) Among Obese Patients

2012 ◽  
Vol 22 (11) ◽  
pp. 1686-1689 ◽  
Author(s):  
M. Giuricin ◽  
C. Nagliati ◽  
S. Palmisano ◽  
C. Simeth ◽  
F. Urban ◽  
...  
Keyword(s):  
Obese Patients ◽  
Term Efficacy ◽  
Short And Long Term

Baroreceptors, baroreceptor unloading, and the long-term control of blood pressure

2005 ◽  
Vol 288 (4) ◽  
pp. R819-R827 ◽  
Author(s):  
Terry N. Thrasher
Keyword(s):  
Animal Studies ◽  
Sympathetic Nerve Activity ◽  
Human Subjects ◽  
Pressure Change ◽  
Proof Of Concept ◽  
Experimental Proof ◽  
Pulsatile Pressure ◽  
Compliance Map ◽  
The Relationship

Whether arterial baroreceptors play a role in setting the long-term level of mean arterial pressure (MAP) has been debated for more than 75 years. Because baroreceptor input is reciprocally related to efferent sympathetic nerve activity (SNA), it is obvious that baroreceptor unloading would cause an increase in MAP. Experimental proof of concept is evident acutely after baroreceptor denervation. Chronically, however, baroreceptor denervation is associated with highly variable changes in MAP but not sustained hypertension. The ability of baroreceptors to buffer imposed increases in MAP appears limited by a process termed “resetting,” in which the threshold to fire shifts in the direction of the pressure change and if the pressure elevation is maintained, it leads to a rightward shift in the relationship between baroreceptor firing and MAP. The most common hypothesis linking baroreceptors to changes in MAP proposes that reduced vascular distensibility in baroreceptive areas would cause reduced firing at the same pulsatile pressure and, thus, reflexively increase SNA. This review focuses on effects of baroreceptor denervation in the regulation of MAP in human subjects compared with animal studies; the relationship between vascular compliance, MAP, and baroreceptor resetting; and, finally, the effect of chronic baroreceptor unloading on the regulation of MAP.

scholarly journals Bariatric Surgery—from the Non-surgical Approach to the Post-Surgery Individual Care: Role of Endoscopy in Bariatric Therapy

2021 ◽  
Author(s):  
Dörte Wichmann ◽  
Dietmar Stüker ◽  
Ulrich Schweizer ◽  
Alfred Königsrainer ◽  
Rami Archid
Keyword(s):  
Flexible Endoscopy ◽  
Study Data ◽  
Obese Patients ◽  
Endoscopic Bariatric Therapy ◽  
Post Surgery ◽  
Lipid Metabolism Disorders ◽  
Individual Care ◽  
Treatment Of Obesity

Obesity is the underlying constant for the development of the most common modern diseases such as insulin resistance, high blood pressure, lipid metabolism disorders, non-alcoholic steatohepatitis (fatty liver), joint problems and various malignancies. The role of endoscopic diagnostic and therapy in obese patients is highlighted in this chapter. In this chapter all devices and methods used in flexible endoscopy for diagnostic and treatment in obese patients are introduced. Role of endoscopy is presented in three parts: in preoperative setting, in post-operative complication management and instead of surgery as endoscopic bariatric therapy. If possible presentation of the effectiveness is compiled with study data. Finally, the interaction between endoscopy and surgery in the treatment of obesity is complex, essential and promising. Endoscopy is indispensable in preoperative preparation, as a primary therapeutic approach, and also in the detection and treatment of acute complications and long-term complications of obesity surgery.

scholarly journals Observations on obese patients eating isocaloric reducing diets with varying proportions of carbohydrate

1970 ◽  
Vol 24 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Cathryn E. A. Hood ◽  
J. M. Goodhart ◽  
R. F. Fletcher ◽  
Josephine Gloster ◽  
P. V. Bertrand ◽  
...  
Keyword(s):  
Weight Loss ◽  
Term Treatment ◽  
Obese Patients ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Simple Obesity ◽  
Treatment Of Obesity ◽  
Sparing Effect

1. Diets containing 1000 kcal/day with varying proportions of carbohydrate (CHO) were fed to four women with simple obesity. The patients were given, in various sequences and for 8 days in each instance, diets in which 3, 6, 12, 25 or 50% of the calories were supplied by sucrose.2. No significant difference in the rate of weight loss was found when the diets of graded CHO content were fed and mean weight loss was 1.2 kg/week.3. The high-CHO diets were antiketogenic; there was no daily relationship between urinary ketones and sodium. The 25 and 50% CHO diets had a nitrogen-sparing effect.4. A 1000 kcal/day diet with about a third of the calories derived from CHO leads to a useful rate of weight loss and minimum changes in body chemistry. This finding may have implications in the long-term treatment of obesity.

scholarly journals Once weekly semaglutide for treatment of obesity

2021 ◽  
Vol 2 (3) ◽  
pp. 01-04
Author(s):  
Nasser Mikhail
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Animal Studies ◽  
Search Terms ◽  
Patients With Diabetes ◽  
The Difference ◽  
Treatment Of Obesity

Background: Once weekly (OW) semaglutide 0.5-1.0 mg is a glucagon-like type-1 receptor agonist (GLR-1 RA) approved for treatment of type 2 diabetes and is currently under evaluation for treatment of obesity at a higher dose of 2.4 mg OW. Objective: to provide an appraisal of WO semaglutide 2.4 mg for treatment of obesity. Methods: Pubmed research up to March 22. Randomized trials, pertinent animal studies, and reviews are included. Search terms were glucagon-like type 1 receptor agonists, weight loss, obesity, semaglutide, safety, efficacy. Results: WO semaglutide 2.4 mg was evaluated as a weight loss agent in 3 well-designed clinical trials of 68 week-duration. In one trial including patients with type 2 diabetes, the difference in weight loss from baseline to week 68 between OW semaglutide and placebo was - 6.2 percentage points (95% CI, -7.3 to -5.2; P<0.0001). In the other 2 studies that excluded patients with diabetes, the difference in weight loss between OW semaglutide and placebo ranged between -10.3% and -12.4%. A significantly higher proportion of participants in the semaglutide groups vs placebo groups achieved at least 5% of weight loss. The most common adverse effects of semaglutide were related to the gastrointestinal (GI) system. Across these 3 trials, premature discontinuation of OW semaglutide occurred in 6-7% vs 3% in placebo groups. Conclusions: OW semaglutide may be a promising agent for treatment of obesity irrespective of presence of type 2 diabetes. Further studies are needed to establish its long-term safety and efficacy.

CO2 Laser Offers Long-Term Efficacy

2008 ◽  
Vol 39 (9) ◽  
pp. 31
Author(s):  
ROBIN TURNER
Keyword(s):  
Co2 Laser ◽  
Term Efficacy

Denosumab Delivered Long-Term Efficacy

2011 ◽  
Vol 41 (17) ◽  
pp. 16-17
Author(s):  
BRUCE JANCIN
Keyword(s):  
Term Efficacy
Sign in / Sign up

Export Citation Format

Share Document